Interventional eyelid procedure with TearCare technology shows promise in dry eye treatment
TearCare technology, an interventional eyelid procedure developed by Sight Sciences, Inc, has demonstrated significant superiority over traditional Restasis prescription eyedrops in treating dry eye disease, according to Phase 1 trial results presented at the American Academy of Optometry’s annual meeting.
The SAHARA randomized controlled trial showed consistent and substantial improvements in various objective measures of dry eye, including tear break up time, meibomian gland health, and corneal/conjunctival health, when utilizing TearCare. In addition, patient-reported outcomes were comparable and statistically significant for both TearCare and Restasis.
The full presentation can be found here.
Related Content
